Clinical course and prediction of survival in idiopathic pulmonary fibrosis
- PMID: 20935110
- DOI: 10.1164/rccm.201006-0894CI
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease of unknown etiology. The median survival of patients with IPF is only 2 to 3 years, yet some patients live much longer. Respiratory failure resulting from disease progression is the most frequent cause of death. To date we have limited information as to predictors of mortality in patients with IPF, and research in this area has failed to yield prediction models that can be reliably used in clinical practice to predict individual risk of mortality. The goal of this concise clinical review is to examine and summarize the current data on the clinical course, individual predictors of survival, and proposed clinical prediction models in IPF. Finally, we will discuss challenges and future directions related to predicting survival in IPF.
Similar articles
-
A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.Dan Med J. 2015 Apr;62(4):B5069. Dan Med J. 2015. PMID: 25872544 Review.
-
Natural history of idiopathic pulmonary fibrosis.Respir Med. 2015 Jun;109(6):661-70. doi: 10.1016/j.rmed.2015.02.002. Epub 2015 Feb 14. Respir Med. 2015. PMID: 25727856 Review.
-
Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP).BMC Pulm Med. 2019 Apr 11;19(1):75. doi: 10.1186/s12890-019-0830-x. BMC Pulm Med. 2019. PMID: 30971235 Free PMC article.
-
Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis.Rheumatology (Oxford). 2017 Mar 1;56(3):384-389. doi: 10.1093/rheumatology/kew426. Rheumatology (Oxford). 2017. PMID: 28082622
-
Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis.Am J Respir Crit Care Med. 2016 Sep 15;194(6):711-8. doi: 10.1164/rccm.201508-1546OC. Am J Respir Crit Care Med. 2016. PMID: 26938706 Free PMC article. Clinical Trial.
Cited by
-
Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment.Respir Res. 2021 Apr 1;22(1):98. doi: 10.1186/s12931-021-01694-z. Respir Res. 2021. PMID: 33794872 Free PMC article.
-
RNA-sequencing reveals differential fibroblast responses to bleomycin and pneumonectomy.Physiol Rep. 2024 Jul;12(13):e16148. doi: 10.14814/phy2.16148. Physiol Rep. 2024. PMID: 38991987 Free PMC article.
-
A novel tree shrew model of pulmonary fibrosis.Lab Invest. 2021 Jan;101(1):116-124. doi: 10.1038/s41374-020-00476-3. Epub 2020 Aug 9. Lab Invest. 2021. PMID: 32773774
-
A Serological Neoepitope Biomarker of Neutrophil Elastase-Degraded Calprotectin, Associated with Neutrophil Activity, Identifies Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease More Effectively Than Total Calprotectin.J Clin Med. 2023 Dec 8;12(24):7589. doi: 10.3390/jcm12247589. J Clin Med. 2023. PMID: 38137658 Free PMC article.
-
Anti-HSP47 siRNA lipid nanoparticle ND-L02-s0201 reverses interstitial pulmonary fibrosis in preclinical rat models.ERJ Open Res. 2021 Jun 7;7(2):00733-2020. doi: 10.1183/23120541.00733-2020. eCollection 2021 Apr. ERJ Open Res. 2021. PMID: 34109242 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
